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We made corrections and edits according to the reviewers comments and addressed all questions and concerns in the body of the manuscript and Tables, and made changes in Figures 2 and 3.

Introduction
============

An emerging hypothesis is gaining increasing interest and is based on the concept that subtle overexpression of α-synuclein (α-syn) over many decades can either predispose or even cause the neurodegenerative changes that characterize Parkinson's disease (PD). Neurons subjected to higher, non-physiological levels of α-syn might be more likely to be damaged by oligomerization or aggregation of this protein, eventually leading to the formation of α-synuclein-based neuropathological features of the disease ^[@ref-1]^.

It is now well established that both point mutations and large genomic multiplications of the α-syn ( *SNCA*) gene can cause an autosomal-dominant form of PD ^[@ref-2]--\ [@ref-10]^. Furthermore, several association studies investigating genetic variants in the *SNCA* gene have found an increased risk for PD ^[@ref-11]--\ [@ref-19]^. The finding that both qualitative and quantitative alterations in the *SNCA* gene are associated with the development of a parkinsonian phenotype indicates that amino acid substitutions as well as overexpression of wild-type α-syn are capable of triggering a clinicopathological process that is very similar to sporadic PD. Nevertheless, the precise mechanisms leading to α-syn-related pathology in sporadic PD in the absence of any α-syn mutations remain elusive.

The best characterized polymorphism in the *SNCA* gene is the Rep-1 mixed dinucleotide repeat which has been shown to act as a modulator of *SNCA* transcription ^[@ref-14]--\ [@ref-16]^. The DNA binding protein and transcriptional regulator PARP-1 showed specific binding to *SNCA*-Rep1. These data were confirmed by a transgenic mouse model and demonstrated regulatory translational activity ^[@ref-20]^.

Functionally, *SNCA* expression levels in postmortem brains suggest that the Rep-1 allele and SNPs in the 3′ region of the *SNCA* gene have a significant effect on *SNCA* mRNA levels in the substantia nigra and the temporal cortex ^[@ref-21]^.

The promoter region of the *SNCA* gene has been recently examined in more detail in cancer cell lines and also in rat cortical neurons. Regulatory regions in intron 1 and the 5′ region of exon 1 have been shown to exhibit transcriptional activation ^[@ref-22]--\ [@ref-24]^ as well as the NACP-Rep-1 region upstream of the *SNCA* gene ^[@ref-14]--\ [@ref-16],\ [@ref-20],\ [@ref-25]^. Several transcription factors have been identified such as PARP-1 ^[@ref-16]^, GATA ^[@ref-26]^, ZIPRO1, and ZNF219 ^[@ref-22]^ to have an effect on regulating the *SNCA* promoter region.

There is mounting evidence that *SNCA* expression levels could be crucial for maintenance and survival of neurons and its misregulation could play a key role in the development of PD. Thus, the importance of thoroughly investigating the *SNCA* gene to fully understand its cis- and trans-acting elements and factors and for the functional interpretation of the PD-disease associated risk alleles is becoming increasingly clear.

The goal of this study was to investigate transcriptional regulation of the *SNCA* region using a complementary approach, under the hypothesis that conserved non-coding regions of the *SNCA* gene are comprised of transcriptional enhancers or silencers and thus modulate gene expression. This would mean that single nucleotide polymorphisms (SNPs) in these regions could influence the transcriptional pattern of the *SNCA* gene ^[@ref-27]^.

Materials and methods
=====================

Comparative genomics
--------------------

Using comparative genomics, we searched for highly conserved non-coding sequences between human and mouse and identified 34 evolutionary conserved non-coding genomic regions (ncECRs) within the *SNCA* gene that are conserved between human and mouse.

We utilized two complementary browsers (Vista browser ( <http://pipeline.lbl.gov/cgi-bin/gateway2>) and ECR browser ( <http://ecrbrowser.dcode.org/>) to generate a conservation profile by aligning the human *SNCA* gene with its mouse counterpart in a pair-wise fashion. We applied established selection parameters for our search with \>100bp in length and \>75% identity ^[@ref-28],\ [@ref-29]^. In addition to the 111.4kb *SNCA* gene region, we included a 44.5kb upstream and a 50kb downstream intergenic region to also capture surrounding regulatory elements.

We identified 34 ncECRs in the *SNCA* genomic region of 206kb on chromosome 4q21 (Chr.4: 90,961056-91,167082, UCSC Genome Browser on Human Mar. 2006 Assembly) by pair-wise comparison between human and mouse ( [Figure 1](#f1){ref-type="fig"}). Ten of these DNA sequences were located downstream of the *SNCA* gene, 17 were intronic between exon 4 and 5, which is 92kb in length, and five were upstream of the *SNCA* gene ( [Figure 1](#f1){ref-type="fig"}). None of the selected sequences overlapped with known expressed sequence tags (ESTs) or had an open reading frame of more than 20 amino acids in length, suggesting that these ncECRs are non-coding.

![Vista plot from the *SNCA* region on chromosome 4q21.\
Panel shows human-mouse pair-wise comparison of Human genome May 2004 and Mouse Sept. 2005. Pink marked peaks represent ncECRs, turquoise marked peak represent the untranslated region (UTR) of *SNCA*, blue marked peaks represent exons. D1-D10 are conserved regions downstream of *SNCA*. In1-In17 are intragenic conserved regions, and U1-U4-2/3 are upstream of *SNCA*. The black arrow on top shows the transcription orientation.](f1000research-3-6309-g0000){#f1}

Cloning and luciferase assays
-----------------------------

To test, if the ncECRs exhibit enhancer or silencer activity, we cloned all identified regions in specific reporter vectors and measured their luciferase activity after transfection into neuroblastoma cells. For our studies, we used the pGL3 luciferase reporter vectors (Promega, Cat. No. E1751, E1741, E1771, E1761) and the human neuroblastoma cell line SK-N-SH. NcECRs identified through the comparative analysis ( [Supplementary Table 1](#ST1){ref-type="table"}) were cloned upstream of a SV-40 promoter in the pGL3 promoter construct, transfected in SK-N-SH cells and assayed with the Dual-Luciferase ^®^ Reporter Assay System (Promega, Cat. No. E1910).

Some of these regions were combined in one vector because of their close proximity to each other. Primers with specific restriction sites (KpnI, BglII or XhoI from New England Biolabs Inc.) were designed to amplify the conserved elements, and PCR products with specific restriction sites were directly cloned into the pGL3 promoter vector to ensure correct orientation of the genomic elements ( [Supplementary Table 1](#ST1){ref-type="table"}). All constructs were sequenced to ensure that no point mutations were introduced through the amplification and/or cloning process.

For transfection experiments, we used a 96-well format (Nunc, Cat. No. 167008). Cells were plated one day before transfection at a density of 3000--5000 cell/well to reach 90--95% confluency at the time of transfection, luciferase assays were performed 24hrs after transfection. SK-N-SH cells were maintained in Hyclone DMEM media (High Glucose, Fisher Scientific, Cat No. SH30081.02) with 10% Hyclone fetal bovine serum (Fisher Scientific, Cat No. SH30910.03) in 1× glutamine (Life Technologies, Cat. No. 25030-081) and 1× penicillin/streptomycin (Life Technologies, Cat. No. 15140-122). For SK-N-SH cells, we used 1:2 ratio of nucleic acid to transfection reagent (Lipofectamine ^®^ 2000 Transfection Reagent, Life Technologies, Cat No. 11668-019). For the luciferase assay, we used the Dual-Luciferase ^®^ Reporter (DLR™) Assay System (Promega, Cat. No. E1910) according to the manufacturer's instructions in 96-well white plates, flat bottom (E&K Scientific, Cat. No. EK-25075). In this assay, activities of firefly and *Renilla* luciferases were measured sequentially in one sample. All assays were performed in quadruplicate and each experiment was repeated three times. Altogether, 12 data points were ascertained for each conserved region/construct.

Statistical analysis
--------------------

Differences among means were analyzed using two-samples student's t-test. For differences in transcriptional activation of the luc+ gene, ncECRs were tested in quadruplicates in three independent experiments. Differences were considered statistically significant at p\<0.05.

Bioinformatic search for transcription factor binding sites (TFBS) with MatInspector (Genomatix)
------------------------------------------------------------------------------------------------

To estimate the number of potential TFBSs and the number of interacting transcription factors (TFs) that could represent potential candidate proteins for our positive ncECRs, we used MatInspector in an *in silico* approach. We chose two elements for this bioinformatic analysis with MatInspector. The MatInspector software utilizes a large library of matrices for TFBSs to locate matching DNA sequences. The program assigns quality rating to matches and allows quality-based filtering and selection of matches. MatInspector can group similar or functionally related TFBSs into matrix families ^[@ref-30]^.

In addition to the original human-mouse comparison, we added the sequences for dog and cow for comparisons. Only the TFBSs were considered that were present in all four species, in the same orientation, and similar distance to each other. We ran two analyses with 10 and 15 nucleotides distance, respectively. We accepted only models in which at least four TFs can bind in a concerted way. Each TFBS can potentially bind several TFs.

We also computationally tested all possible TFs for interactions with the *SNCA* promoter region, which were retrieved from the proprietary ElDorado database (Genomatix, Munich, Germany). In this database, promoters are defined and ranked by transcription start sites, corresponding known mRNA or EST sequences and by orthologous conservation.

Results
=======

Functional non-coding conserved elements within the *SNCA* genomic locus
------------------------------------------------------------------------

Overall, 12 of 34 conserved non-coding elements exhibited either an increase or reduction of the expression of the luciferase reporter gene ( [Figure 2](#f2){ref-type="fig"} and [Dataset 1](#DS0){ref-type="other"}). Three elements upstream of the *SNCA* gene (U3, U4-1, and U4-3) displayed a significant approximately 1.5 fold (p\<0.009) increase in expression ( [Figure 2A](#f2){ref-type="fig"}). Of the intronic regions, three showed a 1.5 fold increase (I2, I6, I8) and two others showed a 2 and 2.5 fold increase in expression (p\<0.002), I5 and I12, respectively ( [Figure 2B](#f2){ref-type="fig"}). Two elements downstream of the *SNCA* gene showed approximately 2 fold (D1 and D2) and 2.5 fold (D3) increase (p\<0.0009) ( [Figure 2C](#f2){ref-type="fig"}). One element D6 downstream of *SNCA* had a reduced expression of the reporter gene of 0.35 fold (p\<0.0009) of normal activity ( [Figure 2C](#f2){ref-type="fig"}, green) that was also confirmed after cloning the D6 element in a pGL3 control vector ( [Figure 2C](#f2){ref-type="fig"}, insert). The pGL3 control vector contains the SV-40 promoter and a SV-40 enhancer element. The D6 element reduced the expression of the pGL3 control construct by \~50%, confirming that this element represents a repressor. Between 4 and 12 replicates were performed per ncECR.

![Non-coding conserved elements within the *SNCA* genomic locus show changes in luciferase assays.\
Panels **A--C** show the luciferase assay results of ncECRs upstream ( **A**), intragenic ( **B**), and downstream ( **C**) of the *SNCA* gene. The X-axis shows the ncECRs, the Y-axis shows the ratio of luciferase and renilla expression as percentage. Bas=pGL3 basic, Con=pGL3 control, prom=pGL3 promoter construct. All red or green box plot elements represent ncECRs that modulate expression significantly. The box plots show the median (horizontal line within box), the 25 and 75% tiles (horizontal borders of box), and the whiskers show the minimal and maximal values. Panel **C**, insert: Luciferase assay results of D6 element cloned into the pGL3 control vector construct.](f1000research-3-6309-g0001){#f2}

These data provide experimental evidence that a significant proportion of the ncECRs show a regulatory function in the luciferase reporter assay.

*In silico* analysis reveals potential binding of midbrain transcription factors to regulatory conserved regions
----------------------------------------------------------------------------------------------------------------

We performed MatInspector (Genomatix) analysis ^[@ref-30]^ on two elements (I12:chr4:90940532-90940786 and D6: chr4:90855871-90856339, Human Genome assembly NCBI36/hg18) with the highest fold change in the luciferase assay. In addition to the original human-mouse comparison to identify the ncECRs, we added the sequences from dog and cow. Only TFBSs that were present in all four species, in the same orientation, and similar distance to each other were considered. We ran two analyses with 10 and 15 nucleotides distance, respectively. We accepted only models in which at least four TFs can bind in a concerted way. Each TFBS can potentially bind several TFs. Interestingly, using this more restricted model, five factors showed an interaction with the *SNCA* promoter as well as with the ncECRs ( [Figure 3A](#f3){ref-type="fig"}). These factors were the Paired-like homeodomain transcription factor 3 (PITX3), the Homolog of *Drosophila* orthodenticle 2 (OTX2), the Nuclear receptor subfamily 3, group c, member 1 (NR3C1) or glucocorticoid receptor (GCCR), the Androgen receptor (AR), and the general transcription initiation factor TATA box-binding protein (TBP).

![*In silico* analysis reveals midbrain transcription factors binding to two ncECRs.\
**A**. MatInspector network view of *SNCA* promoter interaction with TFs that also potentially bind to two ncECRs (I12 and D6) within the *SNCA* gene. M=gene product is part of metabolic pathway, IN=input gene, TF=transcription factor, ST=gene product is part of signal transduction pathway, green line=matches target promoter **B**. UCSC Genome browser custom track of PD associated SNPs (based on PD Gene metaanalysis), Rep1 allele and functional ECR regions on chromosome 4 (Human Genome Assembly Feb. 2009, GRCh37/hg19).](f1000research-3-6309-g0002){#f3}

It is intriguing to note that by searching for TFs that bind to both the promoter and the functional ncECR, several DNA-binding proteins were found that are linked to dopaminergic regulation and susceptibility for nigrostriatal impairment. Two of these TFs (PITX3 and OTX2) implicated in determination of a dopaminergic phenotype in the substantia nigra emerged from this preliminary search ^[@ref-31],\ [@ref-32]^. PITX3 has shown to be regulated in a negative feedback circuit through the microRNA mi-133b to fine-tune maintenance of dopaminergic neurons ^[@ref-33]^. In an association study, a SNP in the PITX3 promoter was reported to be associated with PD and might dysregulate expression of PITX3 ^[@ref-34]^ suggesting that transcription factors play a critical role not only in the development and differentiation of dopaminergic neurons, but also for cell maintenance and survival of dopaminergic neurons.

GCCR and AR belong to a class of nuclear receptors called activated class I steroid receptors. GCCR is a cytosolic ligand-activated transcription factor that regulates the expression of glucocorticoid-responsive genes. GCCR shows strong anti-inflammatory and immunosuppressive effects. Interestingly, impaired GCCR expression in a mouse model shows a dramatic increase in the vulnerability of the nigrostriatal dopaminergic neurons to a toxic insult of MPTP ^[@ref-35]^.

Taken together, this preliminary *in silico* screen resulted in very intriguing new candidates that might directly regulate *SNCA* expression and could play a role in the pathological processes that underlie PD.

###### 

Data are ratios of luminometer readings for firefly luciferase and renilla luciferase. Ratios were normalized to Prom. Each non-coding element is labeled and data are presented under each element. Elements are organized according to [Figure 2A--C](#f2){ref-type="fig"}.

###### 

Click here for additional data file.

Discussion
==========

A major focus in PD research has been on post-translational modification of α-syn. The alterations seen in PD that were linked to disease pathogenesis were nitrated α-syn and α-syn phosphorylated at serine 129 identified in Lewy bodies and Lewy neurites ^[@ref-36],\ [@ref-37]^, however, the gene transcription as a control point and its regulation in particular cell types or upon cellular signals has only been touched fairly recently in PD-relevant genes.

Our results show that potential regulatory regions are not restricted to the promoter of the *SNCA* gene as discussed in the introduction, but are likely to be located also in other intronic and intergenic regions ( [Figure 3B](#f3){ref-type="fig"}). Comparing our results to similar screens, where conserved regions range from 8--45 elements ^[@ref-38],\ [@ref-41]^, we found a similar number of functional elements in our screen that show a high evolutionary conservation.

Not only the promoter region of a gene drives the transcription/expression of a gene. Also other cis-acting genomic regions within a certain gene, up to several hundred kb away, can serve as enhancers, silencers, or modifiers to ensure the accurate temporal and spatial expression of a gene by recruiting transcription activating or silencing factors that bind to them ^[@ref-38]^. There is ample precedence for this approach to analyze genomic regions of genes implicated in human disease. Mutations in those conserved elements were found to cause human genetic syndromes, for example SALL1/Townes-Brocks syndrome ^[@ref-39]^ or SHH/preaxialpolydactyly ^[@ref-40]^. Other groups have investigated the non-coding regulatory elements within disease genes such as RET (Ret proto-oncogene) and MECP2 (Methyl-CpG binding protein 2) and found multiple regulatory enhancer and silencer elements ^[@ref-38],\ [@ref-41]^.

Transcriptional regulation of dopaminergic neurons
--------------------------------------------------

Computationally determining transcription factor binding sites is a challenging process and multiple prediction algorithms have been developed over the last decade (Cartharius 2005, Wu 2009, Mathelier 2013). Therefore our preliminary data should solely open the discussion and drive novel hypotheses for potential transcription factors that regulate transcription of the *SNCA* locus. Specific TFs seem to be directly involved in neurodegeneration and models of PD. TFs have been shown to be critical regulators for the development, maintenance and survival of dopaminergic neuronal populations ^[@ref-42],\ [@ref-43]^. E.g. forkhead transcription factor ( *Foxa2*) is responsible for early development of endoderm and midline structures. Foxa2 is specifically expressed in postmitotic dopaminergic neurons. Genetically engineered mice that are null for *Foxa2* are not viable, whereas heterozygotes for *Foxa2* develop major motor abnormalities starting at 18 months with an asymmetric posture, rigidity, and bradykinesia ^[@ref-44]^.

Conclusion
==========

This screen of evolutionary conserved genomic elements in the *SNCA* locus showed a number of functionally elements that in an *in vitro* assay modulated the expression of a reporter gene. Furthermore, we identified very intriguing new candidate transcription factors that could directly regulate *SNCA* expression and could, if binding is altered by genetic variants, play a role in the pathological processes that underlie PD. This is the first step to systematically analyze the *SNCA* locus to understand its transcriptional regulation in more detail. Further studies are needed in neuronal tissues (e.g. dopaminergic neurons derived from patient-specific induced pluripotent stem cells) to confirm these findings and expand the analysis to identify *SNCA*-regulating transcription factors. By defining the transcription factors that regulate expression and potentially overexpression of α-synuclein that can lead to neurodegeneration, we will be able to identify targets for novel therapeutic approaches for α-synucleinopathies including Parkinson's disease.

Data availability
=================

*F1000Research*: Dataset 1. Combined normalized raw datasets of Luciferase assays on *SNCA* conserved elements, <http://dx.doi.org/10.5256/f1000research.3281.d37452> ^[@ref-45]^
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Supplementary Table
===================

###### Primer sequences and design for cloned ncECRs.

  -----------------------------------------------------------------------------------------------------------------------
                                                   HIndIII: CCC [AAGCTT]{.ul}                             
  -------- ---------- -------- ------------------- ------------------------------------- -------- ------- ---------------
  D1       146bp      78.10%   chr4:90833665-\     CGG **GGTACC**CACGAAATCGTGCCAAAAAT    601bp            no RE
                               90833810                                                                   

                                                   GGA **AGATCT**aagtcacaaggtcgaggcttt            60C     

  D2       239bp      74.50%   chr4:90844830+\     CGG **GGTACC**tgcgaaattccacacaacat    584bp            no RE
                               90845413                                                                   

                                                   GGA **AGATCT**TCAGCAGATGGCATGGAATA             60C     

  D3-1/2   143bp      72%      chr4:90848813-\     CGG **GGTACC**AAGGGCTGACATTGGAATTG                     no RE
                               90848955                                                                   

           99bp       75.80%   chr4:90849405-\     GGA **AGATCT**CCGCCTCTGAAAATAAGCAA    989bp    60C     
                               90849503                                                                   

  D4       110bp      73.60%   chr4:90850858-\     CGG **GGTACC**GATGCAGCCATCAACTCTGA                     no RE
                               90850967                                                                   

                                                   GGA **AGATCT**tgttggtagGCAGGAGAAATG   944bp    60C     

  D5-1     241bp      75.90%   chr4:90853634-\     CGGGGTACCACTTCCTTGGGTAGGCGAAT                          BglII at 1143
                               90853874                                                                   

  D5-2     114bp      75.40%   chr4:90854429-\     CCGCTCGAGGCTGAGATCACGCCACTGTA         1258bp   60C     use XhoI site
                               90854542                                                                   

  D6-1/2   234bp      83.30%   chr4:90855871-\     GGA **AGATCT**CCATTCCCTCACCTCAAATG    582bp    60C     
                               90856104                                                                   

           190bp      75.30%   chr4:90856150-\     CGGGGTACCTCTGCATGAATGTGCAAACA                          
                               90856339                                                                   

  D7       167bp      72.50%   chr4:90859690-\     GGAAGATCTggggctgtagtgtggaaatc                          no RE
                               90859856                                                                   

                                                   CGGGGTACCGGGCAGTGCATACTTGTCCT         856bp    60C     

  D8-1/2   100bp      75%      chr4:90860722-\     GGAAGATCTAGCTTCTGCCTTGTGTCTCC                          no RE
                               90860821                                                                   

           216bp      75.90%   chr4:90861289-\     CGGGGTACCTTGAAGAACCCAAAATGCAA         1061bp   59C     
                               90861504                                                                   

  I1       192 bps    81.80%   chr4:90871989-\     CCGCTCGAGaggataggctccaaccacct         840bp    60C     BglII at 571
                               90872180                                                                   

                                                   CGGGGTACCCAAATTCGGATCACGTAGGG                          use XhoI site

  I2       154bp      74%      chr4:90878220-\     GGA **AGATCT**caggaattGGTGCAAAATCA    393bp    60C     
                               90878373                                                                   

                                                   CGG **GGTACC**aggggctgaccttcaagatt                     

  I3-1/2   276 bps,   77.50%   chr4:90887100-\     GGAAGATCTtgaatgtgatggttcagcaaa        986bp    60C     no RE
                               90887375                                                                   

           153 bps    76.50%   chr4:90887445-\     CGGGGTACCgggaaggcaccctctaggta                          
                               90887597                                                                   

  I4-1/2   194 bps    75.80%   chr4:90891860-\     GGAAGATCTCCACCCCTCCACTTGACATA         899bp    60C     no RE
                               90892053                                                                   

           100 bps    75.00%   chr4:90892381-\     CGGGGTACCGCAATGGAACTGTGGTGATG                          
                               90892480                                                                   

  I5-1/2   109 bps    76.10%   chr4:90893684-\     GGAAGATCTCAGGCATGATTCCTCCCTTA         705bp    60C     no RE
                               90893792                                                                   

           155 bps    73.50%   chr4:90893990-\     CGGGGTACCCCATCAACATCCCAAGAACA                          
                               90894144                                                                   

  I6       130 bps    74.60%   chr4:90894785-\     GGAAGATCTccttgtgggtattcctgaacat       355bp    60C     no RE
                               90894914                                                                   

                                                   CGGGGTACCGAAGTTGCCTGAGCTCCAAT                          

  I7       187 bps    75.90%   chr4:90897558-\     GGAAGATCTAGATGATGAGCAGGCAGTCC         432bp    60C     no RE
                               90897744                                                                   

                                                   CGGGGTACCcgaaccatagtggaaatcagg                         

  I8       112 bps    76.80%   chr4:90901290-\     CCGCTCGAGaaggcttgattggacattgc         474bp    60C     BglII at 34
                               90901401                                                                   

                                                   CGGGGTACCctggaaagaattggccacaa                          use XhoI site

  I9       199 bps,   75.40%   chr4:90906237-\     GGAAGATCTTGCAATGAAAACCACAATGG         561bp    60C     no RE
                               90906435                                                                   

                                                   CGGGGTACCtgtttatgttctgtattccaccaa                      

  I10      269 bps    74.30%   chr4:90926832-\     GGAAGATCTtgggatgggtgggtaaatAG         899bp    60C     no RE
                               90927100                                                                   

                                                   CGGGGTACCtgtgtcaaggatGGGAAAAAG                         

  I11      108 bps    74.10%   chr4:90929480-\     GGAAGATCTtcaaagcaaagatttttctcca       429bp    60C     no RE
                               90929587                                                                   

                                                   CGGGGTACCtggttccttttagcccaattt                         

  I12      255 bps    77.30%   chr4:90940532-\     GGAAGATCTagggaagaggaaaagcttgg         669bp    60C     no RE
                               90940786                                                                   

                                                   CGGGGTACCAAGGTTGAAAAACCGTGGTG                          

  I13      127 bps,   75.60%   chr4:90945579-\     CCGCTCGAGaggctctgggaccacaatta         578bp    60C     BglII at 328
                               90945705                                                                   

                                                   CGGGGTACCCCTCTTAACTTCTGGGCAACC                         use XhoI site

  I14      100 bps    75.00%   chr4:90958054-\     GGAAGATCTtcccacctagaaccttacagga       701bp    60C     no RE
                               90958153                                                                   

                                                   CGGGGTACCACACTTGAGTGTTATGGACCCTCT                      

  I15      329 bps    76.30%   chr4:90961895-\     GGAAGATCTttcaacgttgttgacacctca        490bp    60C     no RE
                               90962223                                                                   

                                                   CGGGGTACCccaGATAAATGCCATGCAAA                          

  I16      106 bps    75.50%   chr4:90976615-\     GGAAGATCTCCCGTTACCACCTGTTGACT         651bp    60C     no RE
                               90976720                                                                   

                                                   CGGGGTACCgccattcgacgacaggttag                          

  U1       261 bps,   81.60%   chr4:90977921-\     GGAAGATCTCCGTCCTCCTCCTCCTAGTC         883bp    60C     no RE
                               90978181                                                                   

                                                   CGGGGTACCATCACGCTGGATTTGTCTCC                          

  U2-1     105 bps,   76.20%   chr4:90980743-\     GGAAGATCTTTCATGTTTTGTTTTCTCTTTGCT     860bp    59.5C   no RE
                               90980847                                                                   

  U2-2     100 bps,   75.00%   chr4:90981402-\     CGGGGTACCcaccagagttgcagagttgc                          
                               90981501                                                                   

  U3       329 bps,   73.90%   chr4:91004670-\     CCGCTCGAGccatgcagttttccCCAATA         751bp    60C     BglII at 487
                               91004998                                                                   

                                                   CGGGGTACCTCTCTCTCATTTTTGGTTTTGACA                      use XhoI site

  U4-1                         chr4:91,008,097-\   GGAAGATCTCTGAAGTAGGGGGCTCTTCC         535bp    60C     no RE
                               91,008,809                                                                 

                                                   CGGGGTACCGAGTTCTTTGGCAGGAGTGC                          

  U4-2     131 bps,   74.00%   chr4:91009155-\     GGAAGATCTtggagaattcagttgctattgg       837bp    60C     no RE
                               91009285                                                                   

                                                   CGGGGTACCTGTGTTGCCATAGTCACATGTTT                       

  U4-3                         chr4:91,010,061-\   GGAAGATCTAAGAAGAAGCAAGCCACACC         698bp    58C     no RE
                               91,010,758                                                                 

                                                   CGGGGTACCtttctgtagggtttatagtgtcca                      
  -----------------------------------------------------------------------------------------------------------------------
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The paper by Dr. Schüle's team describes on the identification of evolutionary conserved non-coding regions (ncECRs) in the α-synuclein (SNCA) gene and their assessment as candidate regulatory elements. The work coupled *in silico* and cell-based studies. By using a comparative genomic screen between human and mouse the authors identify 32 ncECRs, out of which 11 regions exert an effect on expression level using a luciferase reporter assay approach. Their findings add on previous reports in the field that have shown, using both luciferase reporter system and human brain tissues, that the SNCA gene contains cis-regulatory sites across the 3' and the 5' LD blocks that regulate its expression levels.

The study was well designed and thoroughly executed, the results are of interest to the scientific community of PD-genetics, and provide seeds for follow up studies. The paper is nicely written, logically flows and summarizes the literature in the field.  However, the authors should make major revisions according to the following comments: There is some inconsistency regarding the number of the ncECRs identified in the initial screen between the different sections of the article (32, 34, 37). Please make the corrections where needed.Additional necessary control for the Luciferase experiments is a pGL-(SV40) promoter vector harboring an insert of a scrambled sequence that its size range mimics  the average insert size of the tested ECRs. This is required to control for the 'spacer' effect of ECR lengths.What method was used for the statistical analysis? It is also not clear in the text whether all significant changes were calculated in comparison to the SV-40 promoter-only vector. That should be described in details in the method section.To demonstrate the important implication of this study the authors are recommended to follow up on an event as an example. That is to say, to evaluate the effect of a genetic variation, a PD-associated SNP, on the regulatory function of the corresponding ECR using the luciferase system established in this work. Figure 3 demonstrates overlap between PD associated SNPs and ncECR, connecting these dots will be of high significance.Supp Table: there is a typo in the coordinates of D2. In the footnote include the human genome assembly of the coordinates.Figure 2A X-axis: modify title to 'upstream....'Omit Figure 3A. Instead include a new panel to figure 3B that indicates the position of the putative binding sites of these TFs within SNCA locus.The identification of Transcription Factor Binding Sites (TFBS) is an important step required in order to evaluate the transcriptional regulation network of the SNCA gene. To this end, the computational prediction of TFBS is a classic approach that gives preliminary data but should be interpreted with caution. Integration of the classic approach with new models described in [Mathelier & Wasserman (2013)](http://www.ncbi.nlm.nih.gov/pubmed/24039567) is highly recommended. The relation between TF motifs and *in vivo* binding sites is far from simple. The analysis lacks of information about the context of the identified sequences. TF are highly context-specific, and the same TF typically binds to different genomic binding sites in different conditions. Obtaining information about the context could be helpful in better understanding the possible involvement of the predicted sites as TFBS. While this is beyond the scope of this study, this topic should be thoroughly discussed in the discussion section.

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Schuele

Birgitt

**Competing interests:**None.
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We very much appreciate the careful review and excellent comments, suggestions and future directions of the reviewers. We hope to have addressed all of the comments to the reviewers' satisfaction.

There is some inconsistency regarding the number of the ncECRs identified in the initial screen between the different sections of the article (32, 34, 37). Please make the corrections where needed.

*Thanks so much for the comment. We made changes to reflect the correct number of 34 ncECRs. We combined counts for ncECRs that were located very closely in the luciferase assay to one ncECR therefore different numbers appeared in the text. That has been addressed.*

* *

Additional necessary control for the Luciferase experiments is a pGL-(SV40) promoter vector harboring an insert of a scrambled sequence that its size range mimics the average insert size of the tested ECRs. This is required to control for the 'spacer' effect of ECR lengths.

*We have included in our analysis three controls: 1. The* *pGL3-Basic Vector which lacks eukaryotic promoter and enhancer sequences should not show any transcription activity. 2. The pGL3-Enhancer Vector contains an SV40 enhancer located downstream of luc+ and the poly(A) signal and is showing transcription a very high levels (enhancer element is 246bp in length). 3) pGL3-Promoter Vector contains an SV40 promoter upstream of the luciferase gene (promoter is 202bp in length).*

*Even though we have not directly included a control with scrambled sequence, we think that the ncECR elements that do not change transcription of* *luc* *+ provide enough evidence that the experimental system is valid. Of a total of 34 in silico determined elements, only 12 show an effect of transcriptional regulation. 22 elements did not change expression compared to*  *pGL3-Promoter Vector.*

What method was used for the ***statistical analysis***? It is also not clear in the text whether all significant changes were calculated in comparison to the SV-40 promoter-only vector. That should be described in details in the method section.

* A description of the analysis of luciferase assays was lacking and has now been added as a paragraph at the end of Method section* *Cloning and luciferase assays and reads as follows:*

*"Statistical analysis:*

*Differences among means were analyzed using two-samples student's t-test. For differences in transcriptional activation of the luc+ gene, ncECRs were tested in quadruplicates in three independent experiments. Differences were considered statistically significant at p\<0.05."*

To demonstrate the important implication of this study the authors are recommended to follow up on an event as an example. That is to say, to evaluate the effect of a genetic variation, a PD-associated SNP, on the regulatory function of the corresponding ECR using the luciferase system established in this work. Figure 3 demonstrates overlap between PD associated SNPs and ncECR, connecting these dots will be of high significance.

*This is an excellent suggestion and will definitely be conquered in future work with this system as this is the basis for the understanding of transcriptional regulation of the SNCA locus for potential translational applications. The presented study was intended to understand the basic changes in transcriptional regulation within the SNCA locus.*

* *

Supp Table: there is a typo in the coordinates of D2. In the footnote include the human genome assembly of the coordinates.

*We corrected the coordinates for D2 which was a duplicate of D1 with the correct genomic location chr4:90844830+90845413 and added in the header the corresponding Human Genome assembly NCBI36/hg18 (March 2006).*

Figure 2A X-axis: modify title to 'upstream....'

*Correction has been made. It reads now in Figure 2A " [Upstream]{.ul}SNCA conserved elements". We also changed for consistency Figure 2B to "Intronic [SNCA]{.ul}conserved elements" and capitalized Figure 2C " [D]{.ul}ownstream SNCA conserved elements".*

Omit Figure 3A. Instead include a new panel to figure 3B that indicates the position of the putative binding sites of these TFs within SNCA locus.

*We have modified Figure 3 according to the MatInspector network view with respective changes in the legend. We also included which genomic sequences have been analyzed in the text. Since this is a preliminary in silico analysis, we feel that the overview is sufficient and has to be validated in functional studies. As pointed out below by the reviewer, these analyses have to be taken with care and a grain of salt.*

* *

The identification of Transcription Factor Binding Sites (TFBS) is an important step required in order to evaluate the transcriptional regulation network of the SNCA gene. To this end, the computational prediction of TFBS is a classic approach that gives preliminary data but should be interpreted with caution. Integration of the classic approach with new models described in [Mathelier & Wasserman (2013)](http://www.ncbi.nlm.nih.gov/pubmed/24039567) is highly recommended. The relation between TF motifs and *in vivo* binding sites is far from simple. The analysis lacks of information about the context of the identified sequences. TF are highly context-specific, and the same TF typically binds to different genomic binding sites in different conditions. Obtaining information about the context could be helpful in better understanding the possible involvement of the predicted sites as TFBS. While this is beyond the scope of this study, this topic should be thoroughly discussed in the discussion section.

*Thank you very much for this suggestion. Indeed, further studies are necessary to provide experimental evidence for the binding of predicted transcription factors. The analysis provided in this article was only a first step to model potential transcription factor binding sites and should stimulate further studies.*

*The reference Mathelier and Wasserman has been now included in the Discussion of the manuscript and reads as follows:*

*"Computationally determining transcription factor binding sites is a challenging process and multiple prediction algorithms have been developed over the last decade (Cartharius 2005, Wu 2009, Mathelier 2013). Therefore our preliminary data should solely open the discussion and drive novel hypotheses for potential transcription factors that regulate transcription of the SNCA locus."*

[^1]: BS conceived the study and designed the experiments, and drafted the manuscript. LS carried out the experiments. DT analyzed data. MW carried out *in silico* analysis for transcription factors. All authors were involved in the revision of the draft manuscript and have agreed to the final content.
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